Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$71.41 -1.9%	$72.66	$32.33 ▼ $117.33	$7.72B	0.15	1.18 million shs	1.05 million shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	600 shs
FOLD Amicus Therapeutics	$5.91 -5.3%	$6.06	$5.51 ▼ $12.65	$1.92B	0.51	3.22 million shs	2.98 million shs
ORGO Organogenesis	$4.03 -10.2%	$3.47	$2.28 ▼ $6.71	$569.57M	1.7	1.14 million shs	2.82 million shs
RCKT Rocket Pharmaceuticals	$2.81 -7.9%	$3.88	$2.19 ▼ $26.98	$325.70M	0.67	2.25 million shs	2.31 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	-1.87%	+4.77%	+1.93%	+10.54%	+120.74%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
FOLD Amicus Therapeutics	-5.29%	-4.98%	-1.99%	-11.79%	-44.40%
ORGO Organogenesis	-10.24%	-12.96%	+31.27%	-5.18%	+39.45%
RCKT Rocket Pharmaceuticals	-7.87%	-5.07%	-4.10%	-54.31%	-87.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CORT Corcept Therapeutics	4.7715 of 5 stars	3.5	3.0	0.0	4.3	2.1	4.2	1.9
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	4.1007 of 5 stars	3.4	1.0	0.0	4.3	3.3	0.0	1.9
ORGO Organogenesis	4.4748 of 5 stars	3.3	3.0	0.0	4.3	2.2	4.2	0.6
RCKT Rocket Pharmaceuticals	4.8386 of 5 stars	4.2	3.0	0.0	4.7	1.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	3.00	Buy	$138.25	93.60% Upside
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	174.49% Upside
ORGO Organogenesis	2.67	Moderate Buy	$6.50	61.29% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	561.92% Upside

Current Analyst Ratings Breakdown

Latest CORT, RCKT, DCPH, FOLD, and ORGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ORGO Organogenesis	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/15/2025	ORGO Organogenesis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$685.45M	11.05	$1.22 per share	58.59	$6.49 per share	11.00
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
FOLD Amicus Therapeutics	$528.29M	3.44	N/A	N/A	$0.65 per share	9.09
ORGO Organogenesis	$458.76M	1.11	$0.19 per share	21.52	$2.09 per share	1.93
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$141.21M	$1.16	61.56	38.60	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.74	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
ORGO Organogenesis	$860K	-$0.17	N/A	N/A	N/A	-3.46%	-4.00%	-2.26%	8/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest CORT, RCKT, DCPH, FOLD, and ORGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	CORT Corcept Therapeutics	$0.23	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	ORGO Organogenesis	$0.04	-$0.13	-$0.17	-$0.17	$90.77 million	$86.69 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	N/A	3.07	2.96
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
FOLD Amicus Therapeutics	2.02	3.34	2.47
ORGO Organogenesis	N/A	4.12	3.67
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
DCPH Deciphera Pharmaceuticals	70.96%
FOLD Amicus Therapeutics	N/A
ORGO Organogenesis	49.57%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.50%
DCPH Deciphera Pharmaceuticals	4.67%
FOLD Amicus Therapeutics	2.20%
ORGO Organogenesis	33.00%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	106.05 million	84.31 million	Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
ORGO Organogenesis	950	126.85 million	84.99 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

CORT, RCKT, DCPH, FOLD, and ORGO Headlines

Recent News About These Companies

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

2 hours ago | theglobeandmail.com

ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit

July 15 at 4:32 PM | prnewswire.com

Levi & Korsinsky Reminds Rocket Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

July 15 at 9:32 AM | prnewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc ...

July 14 at 11:44 AM | morningstar.comM

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

July 14 at 11:13 AM | globenewswire.com

ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming Deadline

July 14 at 10:52 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 14 at 10:14 AM | globenewswire.com

Rocket Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

July 14 at 9:00 AM | prnewswire.com

ROSEN, A TOP-RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. ...

July 13 at 12:10 PM | gurufocus.com

ROSEN, A TOP-RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

July 13 at 11:23 AM | globenewswire.com

ADOPT TODAY: Meet Rocket

July 12, 2025 | msn.com

Rocket Endurance Hill Climb starts despite rain

July 12, 2025 | msn.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 12, 2025 | gurufocus.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 12, 2025 | prnewswire.com

Join Class Action to Recover Losses from Rocket Pharmaceuticals, Inc ...

July 12, 2025 | stockhouse.com

U.S. Space and Rocket Center launches 'Mission: Cosmic Campout' for stuffed animals

July 12, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 12, 2025 | prnewswire.com

Rocket Lab selects Bollinger for transformation of barge to Neutron landing platform

July 11, 2025 | marinelog.comM

Canadiens News: Laval Rocket GM Wins Bruce Landon Award

July 11, 2025 | sports.yahoo.com

August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT

July 11, 2025 | globenewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Share Price Passes Below 50 Day Moving Average - Should You Sell?

July 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, RCKT, DCPH, FOLD, and ORGO Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$71.41 -1.36 (-1.87%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$72.26 +0.85 (+1.19%)

As of 07:00 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Amicus Therapeutics NASDAQ:FOLD

$5.91 -0.33 (-5.29%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$6.04 +0.14 (+2.28%)

As of 07:04 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Organogenesis NASDAQ:ORGO

$4.03 -0.46 (-10.24%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$4.07 +0.04 (+0.97%)

As of 07:00 AM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.81 -0.24 (-7.87%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.07 (+2.53%)

As of 07:00 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time